TIDMPRTC
PureTech Health PLC
31 July 2019
31 July 2019
PureTech Health plc
PureTech Affiliate Vor Biopharma Appoints Bill Lundberg, MD, to
Board of Directors
PureTech Health plc (LSE: PRTC) ("PureTech"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that its affiliate Vor Biopharma has appointed Bill Lundberg, MD,
to its Board of Directors.
Dr Lundberg is a medical oncologist with deep experience running
drug discovery and development. He was the first employee and
founding chief scientific officer at CRISPR Therapeutics and led
development of the company's first clinical trial application. He
has also held leadership roles at Taligen Therapeutics and Alexion
Pharmaceuticals.
The full release from Vor Biopharma is as follows:
Vor Biopharma Appoints Dr Bill Lundberg to its Board of
Directors
Vor expands expert governance and oversight with highly regarded
physician-scientist and R&D leader
CAMBRIDGE, July 31, 2019 - Vor Biopharma, an oncology company
pioneering engineered haematopoietic stem cells (eHSCs) for the
treatment of haematological cancers, today announced the
appointment of Bill Lundberg, MD, to its Board of Directors.
Dr Lundberg is a medical oncologist with more than 15 years of
experience managing and leading biotechnology research and
development. Most recently, Dr Lundberg served as Chief Scientific
Officer at CRISPR Therapeutics, establishing the company in
Cambridge, Mass. as the first US employee and leading the
development of the company's first clinical trial application. Dr
Lundberg was previously Director and Chief Medical Officer of
Taligen Therapeutics and Vice President and Head of Translational
Medicine at Alexion Pharmaceuticals, where he oversaw R&D from
discovery through early clinical development. Prior to this, Dr
Lundberg held roles of increasing responsibility in drug
development and medical affairs at Xanthus (acquired by Antisoma),
Wyeth (now Pfizer) and Genzyme.
"Patients with haematologic malignancies, particularly myeloid
malignancies, need new, potentially curative treatments. Vor's
completely different approach to unlocking the potential of cancer
immunotherapy for acute myeloid leukaemia and other myeloid
malignancies has immense potential for improving patient outcomes,"
said Dr Lundberg. "I'm excited to help the company advance the
technology, specifically VOR33 for AML, to transform the lives of
patients with blood cancers."
"Bill's proven track record of success building companies and
developing promising novel technologies into clinical stage
medicines makes him a timely addition to the Vor story," said Kush
Parmar, MD, PhD, Managing Partner at 5AM Ventures and Chair of
Vor's Board of Directors. "We welcome his involvement as we begin a
new chapter of Vor's growth and development."
Dr Lundberg also currently serves as an independent Director of
MERUS Therapeutics and a Partner at Cold Spring Partners, LLC. Dr
Lundberg received an MD from Stanford University School of
Medicine, an MBA from Isenberg School of Management and a BS from
Massachusetts Institute of Technology. He completed postdoctoral
training at the Whitehead Institute and trained in internal
medicine and oncology at Brigham and Women's Hospital and
Dana-Farber Cancer Institute.
About VOR33
Vor's lead engineered haematopoietic stem cell (eHSC) product
candidate, VOR33, is in development for acute myeloid leukaemia
(AML). VOR33 is designed to produce healthy blood cells that lack
the receptor CD33, thus enabling the targeting of AML cells through
the CD33 antigen while avoiding toxicity to the blood and bone
marrow. Currently, treating AML with therapy that targets CD33 can
be effective but may be limited in dose and duration due to
toxicity to the blood and bone marrow. By rendering healthy blood
and bone marrow cells 'invisible' to CD33-targeted therapies, VOR33
aims to significantly improve the therapeutic window and
effectiveness of these AML therapies with potential to broaden
clinical benefit to different patient populations.
About Vor Biopharma
Vor Biopharma is working to dramatically change the treatment
paradigm of haematological cancer treatments by developing
engineered haematopoietic stem cells (eHSCs) to enable novel
approaches to cancer therapy. Vor's eHSCs are designed to generate
healthy, fully functional cells with specific advantageous
modifications, for example to protect the blood and bone marrow
from the toxic effects of antigen-targeted therapies, protecting
healthy cells from depletion but leaving tumour cells
vulnerable.
Vor's platform could potentially be used to change the treatment
paradigm of both haematopoietic stem cell transplants and
antigen-targeted therapies such as antibody drug conjugates,
bispecific antibodies and CAR-T cell treatments. A proof-of-concept
study for Vor's lead program has been published in Proceedings of
the National Academy of Sciences.
Vor is based in Cambridge, Mass. and has a broad intellectual
property base including in-licenses from Columbia University, where
foundational work was conducted by inventor and Vor Scientific
Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was founded by Dr
Mukherjee and PureTech Health and is supported by leading investors
including 5AM Ventures and RA Capital Management, Johnson &
Johnson Innovation, Novartis Institutes for BioMedical Research and
Osage University Partners.
About PureTech
PureTech (LSE: PRTC) is an advanced biopharmaceutical company
developing highly differentiated medicines for dysfunctions of the
Brain-Immune-Gut (BIG) axis. The company has gained deep insights
into the connection between these systems and the resulting role in
diseases that have been resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech is developing new categories of medicines with the
potential to have great impact on people with serious
disorders.
PureTech is advancing a rich pipeline of innovative therapies
with an unbiased, nimble, and capital efficient R&D model
across its affiliates and its internal R&D pipeline. PureTech's
pipeline comprises two dozen product candidates, including several
clinical-stage programmes and one product that has been cleared by
the US Food and Drug Administration (FDA). The PureTech pipeline
includes ground-breaking platforms and therapeutic candidates that
were developed in collaboration with some of the world's leading
experts.
PureTech's internal pipeline is centred on lymphatic targeting
and tissue-selective immunomodulation for the potential treatment
of immune and central nervous system disorders, lymphatic
conditions, and cancers. The company is advancing multiple
platforms to enable oral administration of therapies directly into
the lymphatic system, regulate lymphatic flow and function, and
target immunosuppressive mechanisms in oncology. For more
information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAAXFDALNEFF
(END) Dow Jones Newswires
July 31, 2019 08:40 ET (12:40 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024